HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Inclusion criteria

• Age range of 18-75 years old (inclusive of both ends), gender not limited when signing the informed consent form
• ECOG performance status 0 or 1
• Life expectancy of greater than or equal to 12 weeks.
• Subjects with unresectable local advanced or metastatic pancreatic cancer, and pancreatic duct adenocarcinoma confirmed by histopathology
• Provide tumor tissue blocks fixed in formalin, embedded in paraffin, or unstained tumor specimen sections, which can be archived or freshly obtained within 3 years prior to the first study treatment (fresh acquisition is preferred).
• At least one measurable lesion is present according to the efficacy evaluation criteria for pancreatic cancer (RECIST 1.1)

Exclusion criteria

• Accompanied by untreated or active central nervous system (CNS) tumor metastasis
• Failure to recover toxicity and/or complications from previous interventions to NCI-CTCAE ≤ Level 1 or the levels specified by inclusion and exclusion criteria
• Subjects known or suspected to have interstitial pneumonia
• According to the common adverse reaction event evaluation criteria NCI-CTCAE v5.0, patients with ≥ grade 3 serous fluid accumulation or imaging evidence of a large amount of abdominal fluid accumulation (those who require therapeutic puncture and drainage within 2 weeks before starting the study treatment, only those with imaging showing a small amount of ascites and no clinical symptoms can be enrolled)
• Acute or chronic pancreatitis with significant clinical significance